A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action

Trial Profile

A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Apomorphine (Primary) ; Levodopa; Levodopa/carbidopa
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms AM-IMPAKT
  • Sponsors US WorldMeds
  • Most Recent Events

    • 23 Jun 2015 Results presented at the 1st Congress of the European Academy of Neurology.
    • 18 Jun 2015 Results for secondary endpoints in patients treated in the early morning presented at the 19th International Congress of Parkinson's Disease and Movement Disorders.
    • 18 Jun 2015 Results (secondary analysis) presented at the 19th International Congress of Parkinson's Disease and Movement Disorders.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top